ArticleiScience2026
Mechanism of RORα in promoting osteoarthritis through p53 deubiquitination-mediated chondrocyte ferroptosis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive cartilage loss, in which iron dysregulation and ferroptosis contribute to disease progression. Here, we investigated the role of the RORα-p53 axis in regulating chondrocyte ferroptosis during OA. Transcriptomic analysis and experimental models revealed activation of ferroptosis and iron imbalance in OA cartilage, while pharmacological inhibition of ferroptosis alleviated cartilage damage. We identified p53 as a key mediator promoting ferroptotic signaling in chondrocytes and demonstrated that retinoic-acid-related orphan receptor alpha (RORα) acts upstream by stabilizing p53. Mechanistically, RORα recruits the deubiquitinase HAUSP to inhibit p53 ubiquitination, thereby enhancing ferroptotic responses. These findings define a regulatory pathway linking RORα to p53-dependent ferroptosis and cartilage degeneration and provide a potential molecular target for disease-modifying OA therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.